Literature DB >> 6181833

Inactivation of factor VIII coagulant activity by two different types of human antibodies.

M S Gawryl, L W Hoyer.   

Abstract

Human antibodies that inactivate factor VIII procoagulant activity (VIII:C) are heterogeneous in their kinetic properties. We report there here the properties of four type I and four type II antibodies classified according to Biggs et al. Type I antibodies have second-order inactivation kinetics and completely destroy VIII:C when present in high concentration; type II antibodies have more complex kinetics and do not completely inactivate VIII:C even when tested undiluted. The latter properties correspond to the in vivo finding in some patients that there is detectable VIII:C, even though there is also a significant inhibitor titer. It has been suggested that the antibody-antigen complex in these patients retains some VIII:C activity. This is unlikely, however, since protein-A-Sepharose (PAS) did not adsorb any VIII:C activity from mixtures of type II antibodies with normal human plasma. An alternate possibility, reduced VIII:C inactivation due to a steric effect the factor-VIII-related protein (VIIIR, von Willebrand factor), appears to be a more important factor, since three of four type II antibodies had inactivating properties like type I antibodies when they were tested with separated VIII:C instead of plasma. Although the fourth type II antibody did not completely inactivate separated VIII:C the residual coagulant activity was adsorbed from this mixture by PAS. These data indicate that type II anti-VIII:C react with different antigenic determinants than type I antibodies and that these determinants are partially blocked in the factor VIII complex by VIIIR.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6181833

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.

Authors:  Joerg Kahle; Aleksander Orlowski; Diana Stichel; John F Healey; Ernest T Parker; Marc Jacquemin; Manuela Krause; Andreas Tiede; Dirk Schwabe; Pete Lollar; Christoph Königs
Journal:  Blood       Date:  2017-05-15       Impact factor: 22.113

2.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

3.  A monoclonal antibody to von Willebrand factor (vWF) inhibits factor VIII binding. Localization of its antigenic determinant to a nonadecapeptide at the amino terminus of the mature vWF polypeptide.

Authors:  W F Bahou; D Ginsburg; R Sikkink; R Litwiller; D N Fass
Journal:  J Clin Invest       Date:  1989-07       Impact factor: 14.808

Review 4.  Immunologically generated circulating anticoagulants in humans.

Authors:  R L Edwards; C J Wakem
Journal:  Surv Immunol Res       Date:  1984

5.  Rare case of acquired haemophilia and lupus anticoagulant.

Authors:  Devika Gupta; Tathagat Chatterjee; Ajay Sharma; Prosenjit Ganguli; Satyaranjan Das; Sanjeevan Sharma
Journal:  Indian J Hematol Blood Transfus       Date:  2012-10-09       Impact factor: 0.900

6.  Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Authors:  Justin D Walter; Rachel A Werther; Maria S Polozova; Julie Pohlman; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

Review 7.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Haemophilia due to factor VIII inhibitors in a patient suffering from an autoimmune disease: treatment with intravenous immunoglobulin. A case report.

Authors:  A Gianella-Borradori; A Hirt; A Lüthy; H P Wagner; P Imbach
Journal:  Blut       Date:  1984-06

9.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

10.  Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments.

Authors:  C A Fulcher; S de Graaf Mahoney; J R Roberts; C K Kasper; T S Zimmerman
Journal:  Proc Natl Acad Sci U S A       Date:  1985-11       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.